The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Colgate Palmolive
ClinicalTrials.gov Identifier:
NCT00763256
First received: September 26, 2008
Last updated: March 5, 2012
Last verified: March 2012

September 26, 2008
March 5, 2012
May 2006
August 2009   (final data collection date for primary outcome measure)
  • HbA1c Levels in Blood [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Glycated hemoglobin (HbA1c) is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. In this study, blood is taken from each subject and HbA1c levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS).
  • High Sensitivity CRP (C-Reactive Protein) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    CRP is a protein found in the blood and is a marker for inflammation in the body. Inflammation plays a role in the initiation and progression of cardiovascular disease. Blood is taken from each subject and CRP levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS).
  • C-Peptide [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    C-Peptide levels in blood indicate whether or not a person is producing insulin. This peptide is usually found in equal levels to insulin. C-peptide levels measured as a means of distinguishing type 1 diabetes and type 2 diabetes. Blood is taken from each subject and C-Peptide levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS).
  • Gingivitis Score (GI) [ Time Frame: 12 months ] [ Designated as safety issue: No ]

    Units on a scale 0 to 3 (0 = no inflammation,

    1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding)

  • P. Gingivalis [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Subgingival plaque samples were collected from all interproximal (mesial) sites and pooled prior to assessment. The samples will be analysed for the presence of P. gingivalis, using real time PCR to quantitate the numbers of bacteria. P. gingivalis is a non-motile, gram negative, anaerobic, pathogenic bacteria. It is linked to periodontal disease and causes collagen degradation.
Periodontal [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00763256 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics
The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics

To test effectiveness of dentifrice in maintaining periodontal health.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Periodontal Disease
  • Drug: Triclosan, Fluoride
    subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
    Other Name: triclosan/fluoride/copolymer toothpaste
  • Drug: Fluoride
    subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
    Other Name: current marketed fluoride only toothpaste
  • Active Comparator: A
    Intervention: Drug: Triclosan, Fluoride
  • Placebo Comparator: B
    Intervention: Drug: Fluoride
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
August 2009
August 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Poor glycaemic control as evidenced by an HbA1c of >6.0% for the past 12 months
  • Aged 18 to 75 years
  • Able to give informed consent
  • Minimum of 12 teeth
  • Chronic periodontitis as indicated by periodontal probing depths >5mm on at least 6 teeth

Exclusion Criteria:

  • Pregnancy
  • Gross dental caries
  • Prosthetic heart valves, a history of infective endocarditis or any other condition requiring antibiotic cover for dental treatment (rheumatic fever, mitral valve prolapse with regurgitation)
  • Anticoagulant therapy (excluding asprin)
Both
18 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Australia
 
NCT00763256
2004000841/2004/201
Yes
Colgate Palmolive
Colgate Palmolive
Not Provided
Principal Investigator: Gregory Seymour, BDS University of Otago
Colgate Palmolive
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP